Krystal Biotech, Inc. (NASDAQ:KRYS) Given Consensus Rating of “Moderate Buy” by Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS) has earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $185.63.

Several brokerages have recently weighed in on KRYS. Citigroup reaffirmed a “neutral” rating and set a $204.00 price target (up from $195.00) on shares of Krystal Biotech in a research note on Tuesday. Stifel Nicolaus reissued a “buy” rating and issued a $204.00 target price (up from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. Chardan Capital raised their target price on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Krystal Biotech in a research report on Monday.

Krystal Biotech Stock Performance

KRYS opened at $180.37 on Friday. The firm’s 50-day simple moving average is $186.25 and its 200-day simple moving average is $164.61. Krystal Biotech has a twelve month low of $93.95 and a twelve month high of $219.34. The firm has a market cap of $5.15 billion, a price-to-earnings ratio of 96.45 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, August 5th. The company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.03. The company had revenue of $70.28 million for the quarter, compared to the consensus estimate of $65.27 million. The firm’s revenue was up 70283900.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.25) EPS. As a group, sell-side analysts anticipate that Krystal Biotech will post 2 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the transaction, the insider now owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Julian S. Gangolli sold 20,000 shares of the business’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $164.13, for a total transaction of $3,282,600.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total value of $4,394,000.00. Following the completion of the sale, the insider now owns 1,525,882 shares in the company, valued at $268,189,020.32. The disclosure for this sale can be found here. 14.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Krystal Biotech by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after buying an additional 35,632 shares during the last quarter. Jennison Associates LLC grew its stake in Krystal Biotech by 112.5% in the 4th quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock valued at $89,862,000 after purchasing an additional 383,495 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Krystal Biotech by 54.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock valued at $117,189,000 after purchasing an additional 231,255 shares during the period. Dimensional Fund Advisors LP grew its stake in Krystal Biotech by 5.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 550,806 shares of the company’s stock valued at $68,337,000 after purchasing an additional 30,169 shares during the period. Finally, Hood River Capital Management LLC grew its stake in shares of Krystal Biotech by 8.1% during the 1st quarter. Hood River Capital Management LLC now owns 495,586 shares of the company’s stock worth $88,180,000 after acquiring an additional 37,073 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).